Uptake of Sodium-Glucose Cotransporter-2 Inhibitors in Hospitalized Patients With Heart Failure: Insights From the Veterans Affairs Healthcare System

• Published in: Journal of cardiac failure Vol. 30; no. 9; pp. 1086 - 1095
• Main Authors: VARSHNEY, ANUBODH S., CALMA, JAMIE, KALWANI, NEIL M., HSIAO, STEPHANIE, SALLAM, KARIM, CAO, FANG, DIN, NATASHA, SCHIRMER, JESSICA, BHATT, ANKEET S., AMBROSY, ANDREW P., HEIDENREICH, PAUL, SANDHU, ALEXANDER T.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.09.2024
• ISSN: 1071-9164; 1532-8414; 1532-8414
• DOI: 10.1016/j.cardfail.2023.12.018

The use of sodium-glucose cotransporter-2 inhibitors (SGLT2is) in Veterans Affairs (VA) patients hospitalized with heart failure (HF) has not been reported previously. VA electronic health record data were used to identify patients hospitalized for HF (primary or secondary diagnosis) from 01/2019–11/2022. Patients with SGLT2i allergy, advanced/end-stage chronic kidney disease (CKD) or advanced HF therapies were excluded. We identified factors associated with discharge SGLT2i prescriptions for patients hospitalized due to HF in 2022. We also compared SGLT2i and angiotensin receptor-neprilysin inhibitor (ARNI) prescription rates. Hospital-level variations in SGLT2i prescriptions were assessed via the median odds ratio. A total of 69,680 patients were hospitalized due to HF; 10.3% were prescribed SGLT2i at discharge (4.4% newly prescribed, 5.9% continued preadmission therapy). SGLT2i prescription increased over time and was higher in patients with HFrEF and primary HF. Among 15,762 patients hospitalized in 2022, SGLT2i prescription was more likely in patients with diabetes (adjusted odds ratio [aOR] 2.27; 95% confidence interval [CI]: 2.09–2.47) and ischemic heart disease (aOR 1.14; 95% CI: 1.03–1.26). Patients with increased age (aOR 0.77 per 10 years; 95% CI: 0.73–0.80) and lower systolic blood pressure (aOR 0.94 per 10 mmHg; 95% CI: 0.92–0.96) were less likely to be prescribed SGLT2i, and SGLT2i prescription was not more likely in patients with CKD (aOR 1.07; 95% CI 0.98–1.16). The adjusted median odds ratio suggested a 1.8-fold variation in the likelihood that similar patients at 2 random VA sites were prescribed SGLT2i (range 0–21.0%). In patients with EF ≤ 40%, 30.9% were prescribed SGLT2i while 26.9% were prescribed ARNI (P < 0.01). One-tenth of VA patients hospitalized for HF were prescribed SGLT2i at discharge. Opportunities exist to reduce variation in SGLT2i prescription rates across hospitals and to promote its use in patients with CKD and older age.